PYRGF vs. BDTX, BTMD, CTOR, LFVN, KYTX, GLSI, NKTX, ALTS, ELDN, and MOLN
Should you be buying PyroGenesis Canada stock or one of its competitors? The main competitors of PyroGenesis Canada include Black Diamond Therapeutics (BDTX), biote (BTMD), Citius Oncology (CTOR), Lifevantage (LFVN), Kyverna Therapeutics (KYTX), Greenwich LifeSciences (GLSI), Nkarta (NKTX), ALT5 Sigma (ALTS), Eledon Pharmaceuticals (ELDN), and Molecular Partners (MOLN). These companies are all part of the "pharmaceutical products" industry.
PyroGenesis Canada vs. Its Competitors
Black Diamond Therapeutics (NASDAQ:BDTX) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment.
Black Diamond Therapeutics currently has a consensus price target of $11.67, suggesting a potential upside of 306.50%. Given Black Diamond Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Black Diamond Therapeutics is more favorable than PyroGenesis Canada.
PyroGenesis Canada has higher revenue and earnings than Black Diamond Therapeutics. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, PyroGenesis Canada had 1 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 4 mentions for PyroGenesis Canada and 3 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.33 beat PyroGenesis Canada's score of -0.52 indicating that Black Diamond Therapeutics is being referred to more favorably in the media.
Black Diamond Therapeutics has a beta of 2.93, indicating that its stock price is 193% more volatile than the S&P 500. Comparatively, PyroGenesis Canada has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500.
Black Diamond Therapeutics has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. Black Diamond Therapeutics' return on equity of 12.70% beat PyroGenesis Canada's return on equity.
95.5% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are owned by institutional investors. 6.0% of Black Diamond Therapeutics shares are owned by insiders. Comparatively, 47.7% of PyroGenesis Canada shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Black Diamond Therapeutics beats PyroGenesis Canada on 12 of the 16 factors compared between the two stocks.
Get PyroGenesis Canada News Delivered to You Automatically
Sign up to receive the latest news and ratings for PYRGF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PYRGF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PYRGF vs. The Competition
PyroGenesis Canada Competitors List
Related Companies and Tools
This page (NASDAQ:PYRGF) was last updated on 9/5/2025 by MarketBeat.com Staff
Free PYRGF Stock Alerts